Stay updated with breaking news from Gmab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Citigroup cut shares of Genmab A/S (NASDAQ:GMAB – Free Report) from a neutral rating to a sell rating in a research note issued to investors on Monday morning, MarketBeat.com reports. Several other equities research analysts have also commented on GMAB. TheStreet lowered shares of Genmab A/S from a b- rating to a c rating in […] ....
Genmab A/S (NASDAQ:GMAB – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $27.31 and last traded at $27.46, with a volume of 180142 shares. The stock had previously closed at $28.68. Wall Street Analyst Weigh In Several research analysts have recently […] ....
Genmab A/S (NASDAQ:GMAB – Get Free Report) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,740,000 shares, an increase of 8.8% from the December 15th total of 1,600,000 shares. Based on an average trading volume of 847,200 shares, the […] ....
Genmab A/S (NASDAQ:GMAB – Get Free Report) has received a consensus rating of “Hold” from the fifteen brokerages that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company. The average 12-month […] ....
Genmab A/S (NASDAQ:GMAB – Free Report) – Equities researchers at HC Wainwright boosted their FY2023 earnings per share estimates for shares of Genmab A/S in a research note issued to investors on Wednesday, November 8th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $1.06 per share for the year, […] ....